STERIS plc — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
STERIS reported Q2 FY2027 (ended Sept 30, 2026) revenue of $1.588B (+9% YoY; 8% organic constant-currency), with adjusted diluted EPS of $2.94 (+19% YoY). The company raised full-year FY2027 adjusted EPS guidance to $11.35–$11.55 (from $11.10–$11.30), reflecting ~$20M tariff refund benefit in Q2 and ~$0.18 EPS accretion year-to-date. Segment highlights: Healthcare +9%, AST +5%, Life Sciences +18% revenue. The company approved a second restructuring plan (additional $45M total charges, ~$9M annualized savings). Pending Xodus Medical acquisition noted but not closed; updated guidance to follow upon closing.
Why this rating
Solid operational performance (8–9% organic growth, margin expansion) is offsetting by modest tariff-refund dependence. Xodus deal pending. Restructuring is routine cost-management. Revenue $1.59B annualized ~6.4% of $24.2B market cap—incremental but not transformational.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.